Selected published articles related to Aprea AB's project portfolio
The project with the Candidate Drug APR-246 (also called PRIMA-1MET) and the analog PRIMA-1
Articles with Aprea founders, staff and collaborators as authors...
Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS.
PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res. 2011 May 1;17(9):2830-41. Epub 2011 Mar 17.
Ali D, Jönsson-Videsäter K, Deneberg S, Bengtzén S, Nahi H, Paul C, Lehmann S.
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur J Haematol. 2011 Mar;86(3):206-15. Epub 2011 Jan 11.
Bao W, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, Issaeva N, Selivanova G, Stromblad S.
PRIMA-1 (Met) /APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle. 2011 Jan 15;10(2):301-7. Epub 2011 Jan 15.
Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ.
Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2010 Mar 4;29(9):1329-38. Epub 2009 Nov 30.
Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ.
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009 May 5;15(5):376-88.
Zache N, Lambert JM, Wiman KG, Bykov VJ.
PRIMA-1(MET) inhibits growth of mouse tumors carrying mutant p53. Cell Oncol. 2008;30(5):411-8.
Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG.
PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene. 2008 Nov 20;27(51):6571-80. Epub 2008 Jul 28.
Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C.
Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol. 2008 May;141(4):445-53. Epub 2008 Mar 12.
Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG.
PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol. 2008 Mar;86(3):407-11. Epub 2008 Jan 30.
Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman KG, Paul C.
PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol. 2006 Jan;132(2):230-6.
Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Wiman KG.
PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene. 2005 May 12;24(21):3484-91.
Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C, Merup M.
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol. 2004 Nov;127(3):285-91.
Bykov VJ, Issaeva N, Selivanova G, Wiman KG.
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis. 2002 Dec;23(12):2011-8.
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G.
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002 Mar;8(3):282-8.
...and published by others
Roh JL, Kang SK, Minn I, Califano JA, Sidransky D, Koch WM.
p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol. 2010 Dec 15. [Epub ahead of print]
Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM.
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Res Treat. 2011 Jan;125(2):407-20. Epub 2010 Mar 27.
Liang Y, Besch-Williford C, Hyder SM.
PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol. 2009 Nov;35(5):1015-23.
Benakanakere I, Besch-Williford C, Ellersieck M, Hyder S.
Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Endocr Relat Cancer. 2009 Mar;16(1):85-98. Epub 2008 Dec 15.
Magrini R, Russo D, Ottaggio L, Fronza G, Inga A, Menichini P.
PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. J Cell Biochem. 2008 Aug 15;104(6):2363-73.
Liang Y, Besch-Williford C, Brekken RA, Hyder SM.
Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res. 2007 Oct 15;67(20):9929-36.
Liang Y, Besch-Williford C, Benakanakere I, Hyder SM.
Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. Int J Oncol. 2007 Oct;31(4):777-84.
The Wrap53 project
Article with Aprea founder and collaborators as authors
Mahmoudi S, Henriksson S, Farnebo L, Roberg K, Farnebo M.
WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis. 2011 Jan 13;2(1):e114.
Farnebo M.
Wrap53, a novel regulator of p53. Cell Cycle. 2009 Aug;8(15):2343-6. Epub 2009 Aug 8.
Mahmoudi S, Henriksson S, Corcoran M, Méndez-Vidal C, Wiman KG, Farnebo M.
Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage. Mol Cell. 2009 Feb 27;33(4):462-71.
Some p53 review articles
Articles with Aprea founders as authors...
Selivanova G. Semin Cancer Biol.
Therapeutic targeting of p53 by small molecules. 2010 Feb;20(1):46-56. Epub 2010 Mar 3.
Selivanova G, Ivaska J.
Integrins and mutant p53 on the road to metastasis. Cell. 2009 Dec 24;139(7):1220-2.
Hainaut P, Wiman KG.
30 years and a long way into p53 research. Lancet Oncol. 2009 Sep;10(9):913-9.
Bykov VJ, Lambert JM, Hainaut P, Wiman KG.
Mutant p53 rescue and modulation of p53 redox state. Cell Cycle. 2009 Aug 15;8(16):2509-17. Epub 2009 Aug 29.
Soussi T, Wiman KG.
Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007 Oct;12(4):303-12.
Selivanova G, Wiman KG.
Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene. 2007 Apr 2;26(15):2243-54.
Wiman KG.
Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006 Jun;13(6):921-6.
...and published by others
Dey A, Lane DP, Verma CS.
Modulating the p53 pathway. Semin Cancer Biol. 2010 Feb;20(1):3-9. Epub 2010 Mar 1.
McCarthy AR, Hollick JJ, Westwood NJ.
The discovery of nongenotoxic activators of p53: building on a cell-based high-throughput screen. Semin Cancer Biol. 2010 Feb;20(1):40-5. Epub 2010 Mar 4.
Machado-Silva A, Perrier S, Bourdon JC.
p53 family members in cancer diagnosis and treatment. Semin Cancer Biol. 2010 Feb;20(1):57-62. Epub 2010 Mar 3.
Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP.
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009 Dec;9(12):862-73.
Michalak E, Villunger A, Erlacher M, Strasser A.
Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun. 2005 Jun 10;331(3):786-98.
|
